How to Get Prescribed Ozempic: Eligibility, the Visit, and What Happens If You're Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 10 sources cited

Key Takeaways

• Ozempic is FDA-approved for type 2 diabetes and for cardiovascular risk reduction in adults with diabetes and known heart disease. Insurance generally requires documentation of these conditions.
• For weight loss without diabetes, Wegovy or Zepbound are the FDA-approved options. Ozempic for weight loss alone is off-label.
• A prescription requires a clinical visit, lab work showing HbA1c at or above 6.5% (or other diabetes diagnostic criteria), and documentation of why first-line agents like metformin are insufficient.
• Telehealth visits are widely accepted for evaluation, with prescriptions sent to a US-licensed pharmacy.
• If denied, options include appealing with additional documentation, switching to a covered alternative, or considering compounded semaglutide where appropriate.

Direct answer (40-60 words)

To get prescribed Ozempic, schedule a visit (in-person or telehealth) with a licensed provider, complete a medical history review, and have HbA1c or fasting glucose lab work confirming type 2 diabetes. Most insurance plans require diagnosis documentation and prior trials of metformin. For weight loss without diabetes, Wegovy or Zepbound are the FDA-approved choices.

Table of contents

1. The 30-second answer
2. Who is medically eligible for Ozempic
3. What providers need to see in your records
4. The step-by-step process
5. The visit itself: what to expect
6. The labs and tests usually required
7. Insurance coverage and prior authorization
8. If you don't have type 2 diabetes
9. Telehealth vs in-person prescribing
10. What to do if you're denied
11. Common reasons prescriptions get rejected
12. FAQ
13. Sources

Who is medically eligible for Ozempic

Ozempic's FDA-approved indications, as of 2026, are:

1. Type 2 diabetes mellitus in adults, as an adjunct to diet and exercise to improve glycemic control.
2. Cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease.

Patients clearly eligible for an Ozempic prescription:

• Adults diagnosed with type 2 diabetes who need additional glycemic control
• Adults with type 2 diabetes and a history of heart attack, stroke, or coronary artery disease
• Patients on metformin who haven't reached HbA1c targets

Patients not directly eligible for Ozempic on label:

• Adults without type 2 diabetes seeking weight loss (Wegovy is the on-label semaglutide product for weight loss)
• Adults with type 1 diabetes (not approved for type 1)
• People with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome
• Pregnant or breastfeeding individuals (not recommended)
• Children under 18 (not approved for Ozempic; some other GLP-1 medications have pediatric data)

A provider may consider off-label use in some situations, but insurance generally won't pay for off-label use, and ethical/legal considerations vary by clinical context.

What providers need to see in your records

A provider will look for objective evidence of type 2 diabetes before prescribing Ozempic. The standard diagnostic criteria from the American Diabetes Association include any one of the following:

• HbA1c at or above 6.5% confirmed by a second test
• Fasting plasma glucose at or above 126 mg/dL confirmed by a second test
• 2-hour plasma glucose at or above 200 mg/dL during an oral glucose tolerance test
• Random plasma glucose at or above 200 mg/dL in a patient with classic symptoms of hyperglycemia

If you've never been tested or your records are incomplete, your provider will typically order labs at the visit. Results take 1 to 3 days for HbA1c.

For patients seeking Ozempic for cardiovascular risk reduction with diabetes, providers also document:

• Confirmed type 2 diabetes
• A history of cardiovascular disease (myocardial infarction, stroke, peripheral vascular disease, coronary intervention)

For insurance approval, the more documentation in your chart the smoother the process. Useful documents to bring or have ready:

• Recent labs (within 12 months)
• Past glucose readings if you self-monitor
• A list of current medications, especially diabetes medications already tried
• Records of any cardiovascular events
• Body weight and waist circumference
• Family history of diabetes or cardiovascular disease

The step-by-step process

Here's the practical sequence most patients follow:

Step 1: Choose a provider.

• Your primary care provider, an endocrinologist, or a telehealth platform with US-licensed providers.

Step 2: Schedule the visit.

• Initial consultations typically last 20 to 45 minutes for a new diabetes evaluation.

Step 3: Complete the intake.

• Medical history form, current medications, family history, recent labs.

Step 4: Do the visit.

• Provider reviews your history, examines you (in-person) or does a virtual evaluation (telehealth), discusses goals.

Step 5: Lab work if needed.

• HbA1c, fasting glucose, comprehensive metabolic panel, and lipid panel are common.

Step 6: Review of results.

• Once labs return, provider determines whether Ozempic is medically indicated.

Step 7: Prescription sent.

• The provider sends an electronic prescription to your pharmacy of choice.

Step 8: Insurance review.

• The pharmacy submits to your insurance. If prior authorization is required, this can add 1 to 7 business days.

Step 9: Pickup or delivery.

• Once approved, the medication is dispensed. Some pharmacies offer mail-order delivery.

Step 10: Follow-up.

• Most providers schedule a follow-up at 4 to 12 weeks to review tolerance and dose escalation.

The visit itself: what to expect

A typical evaluation visit covers:

History. When was diabetes diagnosed? Have you tried metformin or other agents? What are your blood sugars running? Any cardiovascular history? Any GI conditions? Any history of pancreatitis or thyroid cancer in you or your family?

Symptoms review. Increased thirst, urination, fatigue, blurred vision, weight changes, GI symptoms, palpitations.

Medication reconciliation. All current prescriptions, over-the-counter medications, supplements. This matters because Ozempic can affect absorption of oral medications taken near the same time.

Examination (in-person). Standard vitals (blood pressure, heart rate), body weight and BMI, abdominal exam, neck (thyroid), feet (for diabetes-related changes).

Discussion. Goals (glycemic control, weight, cardiovascular risk reduction). Realistic expectations. Side effect profile. Cost. Pregnancy planning.

Plan. Decision on whether to prescribe, what dose, and follow-up timing.

For telehealth visits, the examination component is replaced with self-reported measurements (weight, blood pressure if you have a cuff at home) and a video review of your visible health.

The labs and tests usually required

A baseline workup before starting Ozempic typically includes:

Test	Why
HbA1c	Confirms diabetes and sets a baseline
Fasting glucose	Confirms diagnosis if HbA1c is borderline
Comprehensive metabolic panel	Kidney and liver function baseline
Lipid panel	Cardiovascular risk assessment
TSH	Baseline thyroid function (because of the medication's thyroid label warning)
Pregnancy test (if applicable)	Ozempic is not recommended in pregnancy

Some providers add lipase and amylase to establish a baseline given the small risk of pancreatitis on GLP-1 medications. Not all do; it's not strictly required by guidelines.

If you've had recent labs (within 6 to 12 months), your provider may use those instead of repeating. For the first prescription, expect at least HbA1c to be checked.

Insurance coverage and prior authorization

Most US commercial insurance plans cover Ozempic for type 2 diabetes when criteria are met. Common prior-authorization requirements:

• Documented diagnosis of type 2 diabetes (ICD-10 codes E11.x)
• HbA1c above a threshold, often 7.0% or higher
• Trial of metformin for at least 3 months unless contraindicated
• For 2.0 mg dose: documentation of inadequate response at 1.0 mg

Medicare Part D coverage of Ozempic for diabetes is widespread. Coverage for cardiovascular risk reduction is more variable.

Medicare and most commercial plans do not cover Ozempic for weight loss without diabetes, since this is off-label use. Even with a diabetes diagnosis, plans differ in formulary placement, copays, and prior authorization rules.

The Novo Nordisk Ozempic savings card can reduce out-of-pocket costs for commercially insured patients who meet eligibility criteria. It is not available for government-insured patients (Medicare, Medicaid, Tricare). Eligibility and copay caps change periodically.

For patients without insurance coverage, full retail cost for Ozempic averages around $968 to $1,029 per monthly pen as of early 2026.

If you don't have type 2 diabetes

If your interest in Ozempic is for weight loss and you don't have diabetes, the more straightforward route is to ask your provider about Wegovy or Zepbound, which are FDA-approved specifically for chronic weight management.

Eligibility criteria for Wegovy or Zepbound:

• BMI of 30 or higher (obesity), or
• BMI of 27 to 29.9 with at least one weight-related condition (hypertension, dyslipidemia, type 2 diabetes, sleep apnea, cardiovascular disease, fatty liver, etc.)
• Adult (18 or older for Wegovy, with 12+ approved on Wegovy in 2022 for adolescent obesity)

Insurance coverage for weight-loss medications is improving but still uneven. Many commercial plans now cover Wegovy or Zepbound for patients meeting the criteria, often with prior authorization. Medicare currently does not cover GLP-1 medications when prescribed solely for weight loss, although coverage for Wegovy under cardiovascular indications is being implemented as of 2025.

For patients without coverage or whose insurance denies brand-name weight-loss medications, a third path is compounded semaglutide or compounded tirzepatide prescribed through a state-licensed compounding pharmacy. Compounded products are not FDA-approved and are not interchangeable with brand-name drugs. They are prescribed by licensed providers in response to specific patient needs, often when commercial products are unavailable, prohibitively expensive, or otherwise unsuitable.

For more on the differences, see /articles/comparison-hub/compounded-vs-brand-name-glp-1-medications/ and /articles/glp1-hub/who-qualifies-for-glp1-medications/.

Telehealth vs in-person prescribing

Telehealth has expanded significantly for GLP-1 prescribing. The pros and cons:

Telehealth advantages:

• Convenient scheduling
• No transportation needed
• Often faster from intake to prescription
• Records can be uploaded electronically
• Strong fit for medication management once diagnosis is established

Telehealth limitations:

• No physical examination
• Initial diabetes diagnosis is harder to confirm without in-person labs
• State licensing rules limit which telehealth providers can prescribe in your state
• Some insurance plans require in-person visits for first GLP-1 prescription

In-person advantages:

• Full physical exam
• Same-visit lab draw at many practices
• May be required by some insurance plans
• Established relationships with primary care or endocrinology

For a first-ever Ozempic prescription, especially in patients with complex history, an in-person visit is often the better starting point. For ongoing prescriptions or patients with established diabetes diagnoses, telehealth follow-up is widely accepted.

What to do if you're denied

Insurance denials are common and not the end of the road. Common steps after a denial:

1. Read the denial letter carefully. It will state the specific reason (missing documentation, step therapy not completed, off-label use, etc.).

2. Ask your provider for a peer-to-peer review. Most insurance plans allow the prescribing provider to discuss the case directly with an insurance medical director. Approval rates after peer-to-peer review are generally favorable when documentation is solid.

3. File a formal appeal. Submit additional documentation: lab results, treatment history, clinical reasoning. Appeals typically take 30 to 60 days for resolution.

4. Check for manufacturer assistance. Novo Nordisk offers patient assistance programs for those who qualify based on income and insurance status.

5. Consider alternatives. If Ozempic is denied but you have type 2 diabetes, alternatives like Trulicity (dulaglutide) or Bydureon may be covered. For weight loss, Wegovy or Zepbound may be more appropriate.

6. Compounded options. Where medically appropriate and legally available, compounded semaglutide prescribed through a licensed provider and state-licensed pharmacy is an option that some patients pursue. Cost is typically lower than brand-name products. The product is not FDA-approved and not interchangeable with Ozempic.

Common reasons prescriptions get rejected

Reason	Fix
Missing diabetes diagnosis	Provide HbA1c results above 6.5%
Step therapy not completed	Document trial of metformin (or contraindication) for at least 3 months
Off-label use for weight loss	Switch to Wegovy or Zepbound for weight indication
Wrong ICD-10 code on the claim	Provider corrects coding and resubmits
Plan does not cover GLP-1 class	Check formulary alternatives
Quantity limit issues	Provider documents the medical need for the prescribed quantity
Pharmacy supply issue	Switch pharmacies or wait for restocking

If your initial prescription is rejected at the pharmacy, the pharmacist will usually provide a rejection reason. Bring that information back to your provider, who can address the specific problem.

FAQ

What do I need to get prescribed Ozempic? A clinical visit with a licensed provider, lab work confirming type 2 diabetes (HbA1c at or above 6.5% is the typical threshold), and documentation that supports medical necessity. For insurance coverage, a trial of metformin for at least 3 months is often required unless contraindicated.

Can I get Ozempic without type 2 diabetes? On-label, no. Ozempic is approved for type 2 diabetes. For weight loss without diabetes, Wegovy and Zepbound are the FDA-approved options. Some providers prescribe Ozempic off-label for weight loss, but insurance generally won't cover it in that scenario.

Will my doctor prescribe Ozempic just for weight loss? Some providers will prescribe off-label, but most prefer to use the FDA-approved weight-management medications (Wegovy or Zepbound). Off-label prescribing has insurance and regulatory implications that vary by state and practice.

How long does it take to get an Ozempic prescription? Same-day to one week from the initial visit, depending on whether labs are needed and how quickly insurance prior authorization clears. The pharmacy step typically adds 1 to 7 business days after the prescription is sent.

Can I get Ozempic through telehealth? Yes, in many cases. Telehealth providers licensed in your state can evaluate, order labs, and prescribe. For a brand-new diabetes diagnosis, in-person evaluation is often more efficient.

Does insurance cover Ozempic? Most commercial plans cover Ozempic for type 2 diabetes when criteria are met. Coverage for off-label weight loss is rare. Prior authorization is common; expect documentation of diabetes diagnosis and prior medication trials.

What labs are needed? Typically HbA1c, fasting glucose, comprehensive metabolic panel, lipid panel, and TSH. Some providers add lipase and amylase as a baseline. Pregnancy test if applicable.

Can I get Ozempic if I'm prediabetic? Ozempic is not approved for prediabetes. Wegovy is approved for chronic weight management in adults with overweight or obesity (often the underlying issue in prediabetes). A provider may discuss alternatives.

What if my insurance denies it? Ask your provider to request a peer-to-peer review with the insurance medical director. File a formal appeal with additional documentation. Consider covered alternatives or, where appropriate, compounded semaglutide prescribed through a licensed provider.

Can I switch from Ozempic to Wegovy? Yes, with provider guidance. The two share an active ingredient but at different doses. Switching usually involves restarting the titration schedule at the new product's starting dose.

How much does Ozempic cost without insurance? Retail price averages roughly $968 to $1,029 per monthly pen as of early 2026. Manufacturer savings cards can reduce out-of-pocket costs for commercially insured patients but don't help cash-paying patients.

Can I get Ozempic if I have type 1 diabetes? No. Ozempic is approved only for type 2 diabetes. Some research is exploring GLP-1 medications as adjuncts in type 1 diabetes, but they are not FDA-approved for that use.

Sources

1. US Food and Drug Administration. Ozempic (semaglutide) prescribing information. Novo Nordisk. Updated 2024.
2. American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1).
3. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
4. Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2022. ADA/EASD Consensus Report. Diabetes Care. 2022;45:2753-2786.
5. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
6. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
7. Centers for Medicare and Medicaid Services. Medicare Part D coverage policy for GLP-1 receptor agonists. CMS. 2024.
8. Novo Nordisk. Ozempic Savings Card terms and conditions. Novo Nordisk. 2025.
9. Aroda VR, et al. PIONEER 1: efficacy and safety of oral semaglutide. Diabetes Care. 2019;42:1724-1732.
10. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. Bydureon is a registered trademark of AstraZeneca. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.